Jamjoom Pharma JV secures $29.5mln financing in Algeria - ZAWYA

Algeria's pharmaceutical sector took a significant step forward in 2025 as Jamjoom Pharma's joint venture secured $29.5 million in fresh financing, signaling renewed confidence in the North African nation's healthcare market despite macroeconomic headwinds.

The financing package represents a substantial commitment to expanding pharmaceutical manufacturing and distribution capabilities in Algeria, Africa's second-largest economy by nominal GDP. This capital infusion comes at a critical juncture as Algeria diversifies its economy away from hydrocarbon dependency and foreign investors reassess post-pandemic risk profiles across the Maghreb region.

## Why is pharmaceutical financing critical for Algeria right now?

Algeria's healthcare sector faces mounting pressure from a population exceeding 45 million with rising chronic disease prevalence and aging demographics. Pharmaceutical imports consume significant foreign reserves annually, making domestic production capacity a strategic national priority. The government has actively courted foreign manufacturers through regulatory streamlining and tariff incentives, positioning the sector as a non-oil growth pillar. Jamjoom's $29.5M commitment directly addresses this policy objective while reducing the nation's pharmaceutical import bill.

Jamjoom Pharma, the Saudi Arabian healthcare conglomerate with regional footprint across GCC and Levantine markets, has pursued North African expansion systematically over the past five years. The Algerian joint venture—likely structured with a local partner to satisfy Foreign Direct Investment (FDI) requirements—positions the company to capture an underserved market of 450+ million across the Maghreb region. This financing round suggests Jamjoom views Algeria as a manufacturing hub rather than a sales-only territory.

## What does this mean for Algeria's broader investment climate?

The deal validates Algeria's pharmaceutical sector attractiveness despite persistent currency controls and foreign exchange scarcity that have constrained other industries. The $29.5M commitment indicates investor confidence that regulatory and macroeconomic conditions have stabilized sufficiently to justify medium-term capital deployment. For ABITECH's investor audience, this signals deepening integration between Gulf capital and North African healthcare infrastructure—a structural trend likely to accelerate as Saudi Vision 2030 and UAE development strategies prioritize Pan-Arab healthcare networks.

The financing structure—whether debt, equity, or hybrid—remains undisclosed but typically reflects lender confidence in revenue predictability. Pharmaceutical JVs in controlled markets like Algeria often secure favorable terms because demand is inelastic and government procurement provides revenue stability. International finance institutions increasingly view healthcare as a resilience play during macroeconomic volatility.

## How will this impact local pharmaceutical competition?

Algeria's domestic pharma sector, dominated by state-owned enterprises and mid-sized private manufacturers, faces intensified competition from well-capitalized foreign entrants. However, Jamjoom's investment may catalyze sector consolidation, technology transfer, and export-oriented growth that benefits the broader ecosystem. Joint ventures typically require local skill development, supply chain integration, and knowledge spillovers that strengthen downstream suppliers and logistics operators.

The $29.5M injection also signals potential follow-on funding from regional and international development finance institutions, which often syndicate healthcare infrastructure deals. Success here could unlock AFDB (African Development Bank), IFC (World Bank subsidiary), or bilateral funding for competing projects.

---

#